February 11, 2026 01:11 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues
COVID19
Pixabay

Portuguese researchers now discover potential drug combo against COVID-19

| @indiablooms | Aug 25, 2021, at 02:34 pm

Lisbon/UNI/Xinhua: A research team in Portugal has found three existing drugs that can help inhibit COVID-19 effects, the Diario de Noticias of Portugal daily reported Tuesday.

During the pre-clinical research, the team from the Institute of Chemical and Biological Technology of NOVA University Lisbon discovered that the drug combination can reduce the replication of SARS-CoV-2, the virus causes COVID-19, by half, said the report.

"With the drugs, we had identified that the virus only replicated at 50 percent," said Cecilia Arraiano, who leads the team, noting that the synergy could act on the Nsp14, a viral protein responsible for replication, to dampen virus activity.

The drugs could be a potential treatment that helps reduce COVID-19 hospitalization rate, according to the team.

Two of the drugs are over-the-counter medicines for treating other diseases, and the third one is pending market approval, researchers said, without disclosing drug names due to patent concern.

Arraiano said it took them nine months to have a pre-clinical discovery, and now she hopes to have more financial support to push it forward.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.